India's Marksans Pharma rises after US FDA completes inspection at unit

Marksans Pharma

03/11/2023 06:32

** Shares of Marksans Pharma  MARK.NS  up as much as 7.3% to
117.15 rupees, their highest since Aug. 14
    ** Generic drugmaker said its unit Time-Cap Laboratories
received establishment inspection report (EIR) for the audit
conducted in Oct. 2023
    ** EIR had no 483s issued, which notifies co of
objectionable conditions
    ** Stock on track for a fifth consecutive session of gains,
if trend holds
    ** Over 4.7 mln shares change hands as of 11:56 a.m. IST,
3.3x the 30-day moving average
    ** Stock last up 5.7%, extending YTD gains to ~98%
    

 (Reporting by Kashish Tandon in Bengaluru)
 ((kashish.tandon@thomsonreuters.com))